Glaxo executive opposes splitting FDA reviews, but editorial in favor

GlaxoSmithKline's R&D chairman opposes creation of a separate agency to monitor the safety of FDA-approved drugs. Tachi Yamada said splitting the process is a hazardous idea and drugs should be reviewed in their totality. Separately, a Journal and Constitution editorial supports the proposal to create an agency independent of the FDA because the agency no longer has the trust of the public.

View Full Article in:

Reuters · Journal and Constitution (Atlanta) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC